Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation-Reference-Cited by-同舟云学术

Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation

Published:2020-02-07 Issue:4 Volume:63 Page:1724-1749
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Curreli Francesca¹,Ahmed Shahad¹,Benedict Victor Sofia M.¹,Iusupov Ildar R.²,Belov Dmitry S.²,Markov Pavel O.²,Kurkin Alexander V.²,Altieri Andrea²,Debnath Asim K.¹^ORCID

Affiliation:

1. Laboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, 310 E 67th Street, New York 10065, New York, United States

2. EDASA Scientific, Scientific Park, Moscow State University, Leninskie Gory Bld. 75, 77-101b,Moscow 119992, Russia

Funder

National Institute of Allergy and Infectious Diseases

New York Blood Center

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b02149

Reference67 articles.

1. HIV Entry and Tropism